✦ LIBER ✦

Lycopene: A novel drug therapy in hormone refractory metastatic prostate cancer

✍ Scribed by M.S. Ansari; N.P. Gupta

Book ID: 116955634
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 94 KB
Volume: 22
Category: Article
ISSN: 1078-1439
DOI: 10.1016/j.urolonc.2004.05.009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment in metastatic prostate cancer

Treatment in metastatic prostate cancer with hormone refractory

✍ S. Vitello; F. Vacirca; E. Triglia; G. Giarratano 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 33 KB

Targeted therapy in hormone refractory p

Targeted therapy in hormone refractory prostate cancer

✍ S. Burbridge; S. Chowdhury; P. G. Harper 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 113 KB

Combination therapy in hormone-refractor

Combination therapy in hormone-refractory prostate cancer

✍ Daniel P. Petrylak 📂 Article 📅 2001 🏛 Current Science Inc. 🌐 English ⚖ 45 KB

Future therapies in hormone-refractory p

Future therapies in hormone-refractory prostate cancer

✍ Matthew R. Smith; Joel B. Nelson 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 144 KB

MOLECULAR TRIGGERED THERAPY IN HORMONE-R

MOLECULAR TRIGGERED THERAPY IN HORMONE-REFRACTORY PROSTATE CANCER

✍ C.H. Ohlmann; E. Özgür; U. Engelmann; A. Heidenreich 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Emergence of metastatic hormone-refracto

Emergence of metastatic hormone-refractory disease in prostate cancer after anti-androgen therapy

✍ Edmund Chun Yu Lee; Martin P.R. Tenniswood 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 258 KB

## Abstract The anti‐androgens used in prostate cancer therapy have been designed to interfere with the normal androgen receptor (AR)‐mediated processes that ensure prostate cell survival, triggering tumor cells to undergo programmed cell death. While anti‐androgens were originally designed to trea